source
- Study shows drug development and reimbursement timelines align across four major marketsResearchers published a cross‑sectional analysis in JAMA Health Forum examining how long it takes for a drug to move from the start of clinical trials to receiving reimbursement approval. The anal…
- MapLight dives despite positive data for schizophrenia drugShares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.